Does C-reactive protein modulate T-lymphocyte function in methotrexate-treated rheumatoid arthritis patients?

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Methotrexate (MTX) is a common disease-modifying antirheumatic drug (DMARD) used in RA treatment.
• The role of specific immune cell subsets and inflammatory markers in RA pathogenesis is an area of ongoing research.

Purpose of the Study:

• To investigate the correlation between serum C-reactive protein (CRP) levels and the proportion of CD8+ lymphocytes in patients with rheumatoid arthritis (RA).
• To explore the potential impact of CRP on lymphocyte function in the context of RA treatment with methotrexate.

Main Methods:

• A cohort of 34 patients diagnosed with rheumatoid arthritis was enrolled.
• Patients received oral methotrexate at a single weekly dose of 7.5-10 mg for a duration of 6 months.
• Serum CRP concentrations and peripheral blood CD8+ lymphocyte proportions were measured.
• Statistical analysis, including linear regression, was employed to assess correlations.

Main Results:

• A significant linear correlation was identified between serum CRP concentration and the proportion of CD8+ lymphocytes in the peripheral blood of RA patients.
• The established linear regression equation quantifies this relationship.
• Findings suggest that CRP may exert an inhibitory effect on lymphocyte function in RA patients.

Conclusions:

• C-reactive protein (CRP) is correlated with CD8+ lymphocyte levels in rheumatoid arthritis (RA) patients treated with methotrexate.
• CRP appears to suppress lymphocyte function in RA, potentially by stimulating suppressor mechanisms.
• These findings contribute to understanding the complex immune dysregulation in RA.